Mesenchymal Stem Cells Immunosuppressed IL-22 in Patients with Immune Thrombocytopenia via Soluble Cellular Factors

Wu, Mei; Ge, Hongfeng; Li, Shue; Chu, Hailiang; Yang, Shili; Sun, Xin; Zhou, Zhenxia; Zhu, Xiaoyan

doi:10.1155/2015/316351

Cited by 8 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-classical subsets of monocytes were found to be prominently elevated in patients with active ITP, contributing to the proliferation of platelet-reactive T cells and the production of interferon gamma [45]. Intermediate subsets of monocytes were also found to be increased, leading to the higher levels of tumor necrosis factor (TNF)-α and interleukin (IL)-1β, in negative correlation with platelet counts [42]. A recent publication showed that CD16+ monocytes could promote the development of Th1 cells, but inhibited the proliferation of Tregs and IL-17(+) Th cells, resulting in the imbalance of Th subsets and further contributing to the pathogenesis of ITP [46].…”

Section: Discussionmentioning

confidence: 99%

Differential Expression of MiR-106b-5p and MiR-200c-3p in Newly Diagnosed Versus Chronic Primary Immune Thrombocytopenia Patients Based on Systematic Analysis

Qian

Yan

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: MicroRNAs (miRNAs) have been described to have important roles in primary immune thrombocytopenia (ITP). To gain additional understanding, we have now further evaluated the involvement of miRNAs in ITP. Methods: Microarray experiments were performed to examine the expression profiles of miRNAs and mRNAs in samples from subjects with newly diagnosed ITP (G1), chronic ITP (G2), and normal controls. The systematic Pipeline of Outlier MicroRNA Analysis framework was applied to identify key miRNAs expressed in the G1 and G2 samples. Quantitative PCR and receiver operator characteristic curves were used to confirm the performance of key miRNAs. Results: Compared with normal controls, 14 miRNAs (12 over-expressed and 2 under-expressed) and 7 over-expressed miRNAs were identified as key in G1 and G2 samples, respectively. miR-106b-5p, miR-200c-3p, and miR-92a-3p exhibited significantly different expression profiles among the groups. In particular, miR-106b-5p and miR-200c-3p were expressed at higher levels in patients with ITP compared to the normal controls. Furthermore, these two miRNAs expressions were even higher in patients with chronic ITP. Conclusion: MiR-106b-5p and miR-200c-3p may represent valuable biomarkers of ITP, although further studies are needed to confirm and assess the value of these potential biomarkers at various stages of ITP.

show abstract

Section: Discussionmentioning

confidence: 99%

Differential Expression of MiR-106b-5p and MiR-200c-3p in Newly Diagnosed Versus Chronic Primary Immune Thrombocytopenia Patients Based on Systematic Analysis

Qian

Yan

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…3 In previous studies, alizarin has been used for staining and has been widely used in experiments on osteoporosis, bone marrow growth, and calcium deposits in the skeletal and vascular systems. [4][5][6][7][8][9][10] In addition to being a dye, alizarin has unexplained biological activities. The formation of biofilms and hyphal growth in Candida albicans is inhibited by alizarin.…”

Section: Introductionmentioning

confidence: 99%

Alizarin as a New Activator of the Aryl Hydrocarbon Receptor Signaling Pathway

Kuan

Lin

et al. 2022

Natural Product Communications

View full text Add to dashboard Cite

Alizarin (1,2-dihydroxyanthraquinone) is a natural red dye extracted from the roots of Rubia cordifolia L. (family Rubiaceae). Alizarin has been used as a biological red stain for calcium. The aryl hydrocarbon receptor (AhR) has critical roles in multiple physiological pathways. This study aimed to determine whether alizarin is an unreported ligand of AhR. In the present study, we investigated the effects on cytochrome P450 (CYP) 1A1 mRNA, protein expression, AhR nuclear translocation, aryl hydrocarbon response element (AHRE) reporter activity, and AhR-specific antagonist following alizarin treatment of cells of the human hepatoma cell line, HepG2, and murine hepatoma cell line, Hepa-1c1c7. Alizarin induced CYP1A1 mRNA and protein expression in HepG2 and Hep-1c1c7 cells. Such induction was not present in C4 (B13NBii1) cells, which are AhR signal deficient, C12 (B15ECiii2) cells, which reduce AhR protein levels. The alizarin-induced responses were blocked by CH-223191, which is an AhR antagonist. Alizarin, the same as with the AhR ligand, induced the nuclear localization of AhR, as well as stimulated the transcriptional activity of AHRE. The results of this study suggest that alizarin is an AhR agonist.

show abstract

“…In vitro, MSCs from bone marrow or adipose origin exhibited immunosuppressive effects and showed a concentration dependence. Clonal proliferation of lymphocytes can be found in ITP patients, but MSCs could inhibit the proliferation and co-stimulatory molecules CD40L and CD80 expression of these lymphocytes in vitro, especially for CD4 + T and CD19 + B cells [ 35 ]. In addition, MSCs can regulate the Th1/Th2 cell balance and promote Tregs, as shown by suppressing Th1-type cytokines, such as IFN-γ and TNF-α, and enhancing Th2-type cytokines, such as IL-4, ultimately restoring immune tolerance and alleviating ITP [ 36 ].…”

Section: Therapeutic Contribution Of Mscs In Itpmentioning

confidence: 99%

Therapeutic potential of MSCs and MSC-derived extracellular vesicles in immune thrombocytopenia

She

et al. 2023

Stem Cell Res Ther

View full text Add to dashboard Cite

Immune thrombocytopenia (ITP) is an acquired autoimmune disease involving a variety of immune cells and factors. Despite being a benign disease, it is still considered incurable due to its complex pathogenesis. Mesenchymal stem cells (MSCs), with low immunogenicity, pluripotent differentiation, and immunomodulatory ability, are widely used in a variety of autoimmune diseases. In recent years, impaired bone marrow mesenchymal stem cells (BMMSCs) were found to play an important role in the pathogenesis of ITP; and the therapeutic role of MSCs in ITP has also been supported by increasing evidence with encouraging efficacy. MSCs hold promise as a new approach to treat or even cure refractory ITP. Extracellular vesicles (EVs), as novel carriers in the “paracrine” mechanism of MSCs, are the focus of MSCs. Encouragingly, several studies suggested that EVs may perform similar functions as MSCs to treat ITP. This review summarized the role of MSCs in the pathophysiology and treatment of ITP.

show abstract

Mesenchymal Stem Cells Immunosuppressed IL-22 in Patients with Immune Thrombocytopenia via Soluble Cellular Factors

Cited by 8 publications

References 36 publications

Differential Expression of MiR-106b-5p and MiR-200c-3p in Newly Diagnosed Versus Chronic Primary Immune Thrombocytopenia Patients Based on Systematic Analysis

Differential Expression of MiR-106b-5p and MiR-200c-3p in Newly Diagnosed Versus Chronic Primary Immune Thrombocytopenia Patients Based on Systematic Analysis

Alizarin as a New Activator of the Aryl Hydrocarbon Receptor Signaling Pathway

Therapeutic potential of MSCs and MSC-derived extracellular vesicles in immune thrombocytopenia

Contact Info

Product

Resources

About